[go: up one dir, main page]

CL2019000169A1 - Derivados de piperidina. - Google Patents

Derivados de piperidina.

Info

Publication number
CL2019000169A1
CL2019000169A1 CL2019000169A CL2019000169A CL2019000169A1 CL 2019000169 A1 CL2019000169 A1 CL 2019000169A1 CL 2019000169 A CL2019000169 A CL 2019000169A CL 2019000169 A CL2019000169 A CL 2019000169A CL 2019000169 A1 CL2019000169 A1 CL 2019000169A1
Authority
CL
Chile
Prior art keywords
piperidine derivatives
formula
rar1
cxcr7
modulators
Prior art date
Application number
CL2019000169A
Other languages
English (en)
Inventor
Hamed Aissaoui
Julien Pothier
Sylvia Richard-Bildstein
Philippe Guerry
Francois Lehembre
Laetitia Pouzol
Shuguang Yuan
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CL2019000169A1 publication Critical patent/CL2019000169A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A DERIVADOS DE PIPERIDINA DE LA FÓRMULA (I) , EN DONDE AR1, AR2, RAR1, R1, R2 Y R3 SON COMO SE DESCRIBE EN LA DESCRIPCIÓN, A SU PREPARACIÓN, A SUS SALES FARMACÉUTICAMENTE ACEPTABLES Y A SU USO COMO PRODUCTOS FARMACÉUTICOS, A COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN UNO O VARIOS COMPUESTOS DE LA FÓRMULA (I) Y EN ESPECIAL A SU USO COMO MODULADORES DEL RECEPTOR CXCR7.
CL2019000169A 2016-07-28 2019-01-22 Derivados de piperidina. CL2019000169A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2016068052 2016-07-28

Publications (1)

Publication Number Publication Date
CL2019000169A1 true CL2019000169A1 (es) 2019-06-21

Family

ID=59656027

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019000169A CL2019000169A1 (es) 2016-07-28 2019-01-22 Derivados de piperidina.
CL2019003281A CL2019003281A1 (es) 2016-07-28 2019-11-15 Derivados de piperidina. (divisional solicitud 201900169)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2019003281A CL2019003281A1 (es) 2016-07-28 2019-11-15 Derivados de piperidina. (divisional solicitud 201900169)

Country Status (32)

Country Link
US (2) US10752620B2 (es)
EP (2) EP3798217B1 (es)
JP (2) JP6655754B2 (es)
KR (2) KR102497091B1 (es)
CN (2) CN109563085B (es)
AR (2) AR109180A1 (es)
AU (2) AU2017302079B2 (es)
CA (1) CA3032017C (es)
CL (2) CL2019000169A1 (es)
CY (1) CY1125016T1 (es)
DK (2) DK3798217T3 (es)
EA (2) EA202091262A1 (es)
ES (2) ES2954152T3 (es)
FI (1) FI3798217T3 (es)
HR (2) HRP20230313T1 (es)
HU (2) HUE062019T2 (es)
IL (2) IL264424B (es)
LT (2) LT3490986T (es)
MA (2) MA54653B1 (es)
MX (2) MX383804B (es)
MY (2) MY199657A (es)
NZ (1) NZ751006A (es)
PH (2) PH12021552605A1 (es)
PL (2) PL3490986T3 (es)
PT (2) PT3798217T (es)
RS (2) RS64130B1 (es)
SG (2) SG10201906942PA (es)
SI (2) SI3798217T1 (es)
TW (3) TWI691494B (es)
UA (2) UA122987C2 (es)
WO (1) WO2018019929A1 (es)
ZA (1) ZA201901256B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11339148B2 (en) * 2018-01-26 2022-05-24 Idorsia Pharmaceuticals Ltd. Crystalline forms of the CXCR7 receptor antagonist (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide
CN114599363A (zh) * 2019-10-31 2022-06-07 爱杜西亚药品有限公司 Cxcr7拮抗剂与s1p1受体调节剂的组合
US20240059688A1 (en) * 2020-12-22 2024-02-22 Luxembourg Institute Of Health (Lih) Conolidine analogues as selective ackr3 modulators for the treatment of cancer
MX2023012365A (es) * 2021-04-19 2023-11-27 Chemocentryx Inc Azetidinil-acetamidas como inhibidores de cxcr7.
BR112024001979A2 (pt) 2021-08-02 2024-04-30 Syngenta Crop Protection Ag Derivados de pirazol microbicidas
CN117396471A (zh) 2021-10-01 2024-01-12 株式会社次代生物科学 新的哌啶衍生物和包含其的用于抑制自分泌运动因子的药物组合物
US20250011314A1 (en) 2021-12-17 2025-01-09 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
EP4238970A1 (en) 2022-03-03 2023-09-06 InterAx Biotech AG Modulators of ackr3 and uses thereof
CN115403510B (zh) * 2022-08-11 2023-04-25 南方医科大学 一种pd-l1/cxcl12双靶点抑制剂、制备方法和用途
TW202434579A (zh) 2022-11-16 2024-09-01 瑞士商先正達農作物保護股份公司 殺微生物的四氫異喹啉衍生物
JP2025539452A (ja) 2022-11-30 2025-12-05 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺微生物テトラヒドロイソキノリン誘導体
TW202439972A (zh) 2022-11-30 2024-10-16 瑞士商先正達農作物保護股份公司 殺真菌組成物
AR131667A1 (es) 2023-01-27 2025-04-16 Syngenta Crop Protection Ag Derivados de pirazol microbiocidas
AR131665A1 (es) 2023-02-01 2025-04-16 Syngenta Crop Protection Ag Composiciones fungicidas
AR132937A1 (es) 2023-06-14 2025-08-13 Syngenta Crop Protection Ag Composiciones fungicidas
WO2025146625A1 (en) 2024-01-03 2025-07-10 Pi Industries Ltd. Pyrazole compounds for combating phytopathogenic fungi
WO2025146624A1 (en) 2024-01-03 2025-07-10 Pi Industries Ltd. Bicyclic heterocyclic amides for combating phytopathogenic fungi
WO2025163143A1 (en) 2024-02-02 2025-08-07 Syngenta Crop Protection Ag Microbiocidal pyrazole derivatives
WO2025172368A1 (en) 2024-02-13 2025-08-21 Syngenta Crop Protection Ag (5-isoxazol-3-yl)-[4-(pyrazol-4-yl)-3,4-dihydro-1h-isoquinolin-2-yl]methanone derivatives for use as fungicides

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102324A1 (en) * 2002-02-28 2004-05-27 Annis Gary David Heterocyclic diamide invertebrate pest control agents
GEP20115290B (en) 2002-11-27 2011-09-26 Incyte Corp 3-aminopyrrolidine derivatives as modulators of chemokine receptors
TW200526626A (en) * 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
EP1670739A4 (en) 2003-10-08 2007-08-08 Bristol Myers Squibb Co CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS
CA2598423C (en) * 2005-02-18 2014-05-27 Astrazeneca Ab Antibacterial piperidine derivatives
CN102271681B (zh) * 2008-11-04 2014-11-12 凯莫森特里克斯股份有限公司 Cxcr7调节剂
WO2012168315A1 (en) 2011-06-09 2012-12-13 Boehringer Ingelheim International Gmbh Substituted piperidines as gpr119 modulators for the treatment of metabolic disorders
WO2013084241A1 (en) * 2011-12-09 2013-06-13 Cadila Healthcare Limited Compounds as inhibitors of renin
AR091516A1 (es) 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
MX359651B (es) * 2012-11-29 2018-10-05 Chemocentryx Inc Antagonistas de cxcr7.
EA028604B1 (ru) * 2013-05-30 2017-12-29 Идорсиа Фармасьютиклз Лтд. Модуляторы рецептора cxcr7
SG11201601225RA (en) 2013-09-04 2016-03-30 Bristol Myers Squibb Co Compounds useful as immunomodulators
CN105814028B (zh) 2013-09-06 2018-02-16 奥瑞基尼探索技术有限公司 作为免疫调节剂的1，2，4‑*二唑衍生物
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
BR112017004589A2 (pt) * 2014-09-10 2018-01-23 Epizyme Inc composto, composição farmacêutica, método para tratar um paciente, uso de um composto, kit, e método para tratar um distúrbio mediado por proteína smyd
CN107001279B (zh) 2014-12-01 2020-10-20 爱杜西亚药品有限公司 Cxcr7受体调节剂
US11339148B2 (en) 2018-01-26 2022-05-24 Idorsia Pharmaceuticals Ltd. Crystalline forms of the CXCR7 receptor antagonist (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide

Also Published As

Publication number Publication date
HRP20230313T1 (hr) 2023-05-12
AU2017302079B2 (en) 2021-07-22
EP3490986B1 (en) 2021-11-24
AU2020204578B2 (en) 2022-03-10
EA037507B1 (ru) 2021-04-06
CN110563717B (zh) 2022-08-09
AR109180A1 (es) 2018-11-07
FI3798217T3 (fi) 2023-05-03
PH12021552605A1 (en) 2023-01-23
SG11201900633XA (en) 2019-02-27
ES2905755T3 (es) 2022-04-12
CY1125016T1 (el) 2023-03-24
TW201932454A (zh) 2019-08-16
RS62855B1 (sr) 2022-02-28
MA45782B1 (fr) 2021-12-31
MA45782A (fr) 2019-06-05
RS64130B1 (sr) 2023-05-31
ES2954152T3 (es) 2023-11-20
WO2018019929A1 (en) 2018-02-01
IL264424B (en) 2021-08-31
SG10201906942PA (en) 2019-09-27
AU2020204578A1 (en) 2020-07-30
AU2017302079A1 (en) 2019-03-21
LT3490986T (lt) 2022-02-10
CL2019003281A1 (es) 2020-05-04
CN109563085B (zh) 2022-08-09
AR115662A2 (es) 2021-02-10
MX2021004000A (es) 2021-06-23
US20190169180A1 (en) 2019-06-06
CN110563717A (zh) 2019-12-13
DK3490986T3 (da) 2022-03-07
TW201922738A (zh) 2019-06-16
ZA201901256B (en) 2021-08-25
DK3798217T3 (da) 2023-05-22
US20200385373A1 (en) 2020-12-10
MX2019001042A (es) 2019-06-10
US10752620B2 (en) 2020-08-25
PL3798217T3 (pl) 2023-06-12
NZ751006A (en) 2021-07-30
TW201806940A (zh) 2018-03-01
EA202091262A1 (ru) 2020-08-13
CN109563085A (zh) 2019-04-02
HRP20211988T1 (hr) 2022-03-18
IL282942A (en) 2021-06-30
SI3798217T1 (sl) 2023-05-31
MY199657A (en) 2023-11-14
TWI691494B (zh) 2020-04-21
KR102497091B1 (ko) 2023-02-06
EP3798217B1 (en) 2023-02-22
KR20200092420A (ko) 2020-08-03
MA54653A (fr) 2021-12-29
PL3490986T3 (pl) 2022-04-04
EP3490986A1 (en) 2019-06-05
JP2019142874A (ja) 2019-08-29
US11306078B2 (en) 2022-04-19
CA3032017C (en) 2023-04-18
JP6655754B2 (ja) 2020-02-26
TWI691497B (zh) 2020-04-21
KR20190034620A (ko) 2019-04-02
MA54653B1 (fr) 2023-04-28
PT3490986T (pt) 2022-02-01
SI3490986T1 (sl) 2022-02-28
BR112019001551A2 (pt) 2019-05-14
MX383804B (es) 2025-03-14
MY198113A (en) 2023-08-03
UA129887C2 (uk) 2025-09-03
JP2019525927A (ja) 2019-09-12
KR102497095B1 (ko) 2023-02-06
PH12019500188A1 (en) 2019-10-21
IL282942B (en) 2022-01-01
HUE057315T2 (hu) 2022-04-28
HUE062019T2 (hu) 2023-09-28
EA201990388A1 (ru) 2019-08-30
CA3032017A1 (en) 2018-02-01
PT3798217T (pt) 2023-05-23
TWI683812B (zh) 2020-02-01
LT3798217T (lt) 2023-05-25
NZ755815A (en) 2025-02-28
JP6655742B2 (ja) 2020-02-26
EP3798217A1 (en) 2021-03-31
UA122987C2 (uk) 2021-01-27
IL264424A (en) 2019-02-28

Similar Documents

Publication Publication Date Title
CL2019000169A1 (es) Derivados de piperidina.
MX2018015216A (es) Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
MX2018015212A (es) Nuevos derivados piperidinilo sustituidos con hetero(arilo), un proceso para su preparacion y composiciones farmaceuticas que los contienen.
CO2018007443A2 (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
MX2017016995A (es) Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
SV2016005171A (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
MX2017016997A (es) Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
JO3807B1 (ar) مشتقات حمض هيدروكسي جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
MX2019013639A (es) Derivados de indol n-sustituidos.
MX2018005268A (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2.
MX2017009505A (es) Derivados de 9h-pirrolo-dipiridina.
MX375099B (es) Derivados de aminotiazol útiles como agentes antivíricos.
CO2017008156A2 (es) Derivados de 1-(4-(4-(pirimidin-5-il)tiazol-5-il)piperazin-1-il)etan-1-ona y análogos de piridina de los mismos como moduladores del receptor cxcr3, composiciones que los comprenden y métodos de elaboración
UY35708A (es) Compuestos novedosos como antagonistas del receptor de ácido lisofosfatidico
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
CO2018003473A2 (es) Nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2020001817A1 (es) Moduladores del receptor c5a
UY36110A (es) Inhibidores de quinasa relacionados con tropomiosina
CY1122381T1 (el) Παραγωγα ιμιδαζοπυριδαζινης ως αναστολεις pi3kbhta
CL2021003348A1 (es) Derivados de piridin–3–ilo.
UY38217A (es) Derivados de 1-imidazotiadiazol-2h-pirrol-5-ona